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α-Tocopherol succinate Nanostructured Lipid carriers for the Ocular delivery of the 
antineoplastic agent  
i. Project Summary  
Overview: Retinoblastoma (RB) is a rare form of cancer that rapidly develops from the immature 
cells of the retina, the light-detecting tissue of the eye. The treatment options of RB has been 
limited to enucleation, external beam radiotherapy, episcleral plaque radiotherapy and 
cryotherapy. α-Tocopherol succinate (αTS), has been proven to an effective apoptogenic agent. It 
can enhance the efficiency of the anticancer agent1. Paclitaxel (Ptx) is a potent chemo agent and is 
widely used in the treatment of various types of cancers. However, clinical use of Paclitaxel is 
limited by systemic toxicity, rapid clearance and resistance2,3. The formulation of paclitaxel poses 
the challenge of incorporation of drug in a Chremophor free and organic solvent free matrix. 
Moreover, the blood-retinal barrier also limits the potential of Ptx. αTS and Ptx when combined 
together can exert a synergistic effect, thus increasing the efficiency while reducing the required 
dose of the anti-cancer agent.  
Intellectual Merit: Paclitaxel a taxane compound, originally derived from the bark of Pacific yew 
is extensively researched and used in treatment of various types of cancers2. Paclitaxel acts by 
binding and inactivating the intracellular proteins necessary for cell survival and functioning, thus 
including cell death3,4. αTS is a succinic acid ester form of Vitamin E, a variate more stable than 
the α-tocopherol1. The normal cells can hydrolyze the αTS to the original α-tocopherol, while the 
cancer cells lack the machinery to convert the ester to the original form, resulting in the cytotoxic 
activity of α-TS. Thus, this mechanism can be implemented along with Ptx for anticancer therapy. 
The conventional methods of treatments in retinoblastoma consists of systemic delivery of 
the chemotherapeutic agents leading to severe side effects and decreased bioavailability5. The 
delivery of drugs by the ocular routes can help overcome this challenge along with advantages 
such as ease of administration, increased precorneal residence time and enhancement in ocular 
bioavailability of drugs6. The NLCs can be pass through the corneal barriers as well as they can 
deliver the drug to the posterior section of eye7. The controlled release of Paclitaxel from the NLC 
will ensure that therapeutic levels of drugs are maintained at the site of action. This will reduce the 
amount of drug required to induce the cytotoxic action. Thus, Paclitaxel and α-Tocopherol 
succinate together can show synergistic activity. The FDA approved paclitaxel formulation 
constitute paclitaxel in Chremophor EL and Ethanol. Due to the inherent toxicity of Chemophor 
and deleterious effects of ethanol on eye8,9, this formulation cannot be used for ocular drug 
delivery. Hence, the objective of this study was to formulate paclitaxel delivery system, without 
chemophor or any organic solvent.  
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This funding opportunity will help advance the nano-formulations in cancer treatment and will 
also help me have project funded from my data. This opportunity will be a boost to seek a future 
position as a scientific researcher. 
